X-Linked Agammaglobulinemia (XLA)

Genetics and Pathogenesis

• X-linked agammaglobulinemia (XLA), also known as Bruton agammaglobulinemia or infantile agammaglobulinemia, is a profound primary immunodeficiency resulting from a severe defect in B-lymphocyte development.
• The disorder is transmitted as an X-linked trait, thereby predominantly affecting males, while female offspring of affected patients can carry the mutated gene.
• The condition is caused by a pathogenic variant in the gene encoding the B-cell protein tyrosine kinase (Btk), which maps to the q22 locus on the long arm of the X chromosome (Xq21.2–22).
• The Btk protein is expressed in all B-lineage cells and plays a critical role in B-cell differentiation, maturation, and signaling.
• Mutation in the BTK gene results in a developmental arrest of B cells, causing a profound absence of circulating B cells and severe hypogammaglobulinemia.
• Although pre-B cells can be found in the bone marrow, the percentage of mature B lymphocytes in the peripheral blood is characteristically less than 1%.
• Cell-mediated immunity is spared; the percentage of T cells is increased, the ratio of T-cell subsets is normal, T-cell function is completely intact, and the thymus appears anatomically normal.

Clinical Manifestations

• Affected male infants typically remain asymptomatic for the first 6 to 9 months of life, as they are protected by maternally transmitted IgG antibodies acquired transplacentally.
• Once maternal antibody levels wane, patients develop severe, recurrent infections caused primarily by extracellular pyogenic organisms, notably Streptococcus pneumoniae and Haemophilus influenzae.
• The most common infectious presentations include sinusitis, otitis media, bronchitis, pneumonia, pyoderma, purulent conjunctivitis, sepsis, and meningitis.
• Physical examination classically reveals marked lymphoid hypoplasia, characterized by small or completely absent tonsils and the absence of palpable lymph nodes.
• Patients with XLA have a uniquely high susceptibility to chronic, frequently fatal central nervous system infections caused by enteroviruses, including echoviruses and coxsackieviruses.
• An enterovirus-associated myositis that clinically resembles dermatomyositis has also been documented in these patients.
• The administration of live attenuated viral vaccines, particularly the oral polio vaccine, can result in vaccine-associated paralytic poliomyelitis.
• While most viral and fungal pathogens are handled normally, patients are prone to Mycoplasma and Ureaplasma urealyticum infections, which can cause severe purulent arthritis in large joints.
• Gastrointestinal infections, particularly with Giardia lamblia, are common and can lead to chronic diarrhea, malabsorption, and weight loss.
• Neutropenia is occasionally observed at the time of diagnosis during active infections, particularly those caused by staphylococcal species or Pseudomonas, which can lead to life-threatening invasive disease.

Laboratory Diagnosis

• The diagnosis is highly suspected when total serum immunoglobulins are exceedingly low (typically <100 mg/dL), with specific concentrations of IgG, IgA, IgM, and IgE falling far below the 95% confidence limits for age-matched controls.
• Patients lack specific functional antibodies; levels of natural isohemagglutinins (antibodies against type A and B red blood cell antigens) and antibodies generated in response to routine immunizations are abnormally low.
• Flow cytometry is a mandatory diagnostic tool and demonstrates a virtual absence (less than 1%) of CD19+ B cells in the peripheral circulation.
• The use of flow cytometry is critical to distinguish XLA from other humoral immunodeficiencies, such as common variable immunodeficiency (CVID), hyper-IgM syndrome, and transient hypogammaglobulinemia of infancy.
• A definitive diagnosis is established through genetic testing to detect pathogenic variants in the BTK gene or the absence of the Btk protein.

Management and Complications

• The cornerstone of medical management is lifelong immunoglobulin replacement therapy (administered intravenously or subcutaneously) to provide passive immunity and prevent recurrent infections.
• Vigilant monitoring and the aggressive use of appropriate prophylactic or therapeutic antibiotics are essential to manage documented infections and decrease morbidity.
• Despite adequate immunoglobulin replacement therapy, some patients continue to experience recurrent infections, and chronic respiratory complications such as severe bronchiectasis and chronic obstructive lung disease may persist.
• Gastrointestinal disease is an increasingly recognized complication, and some patients may develop a chronic colitis that clinically mimics inflammatory bowel disease.